Angiotensin-(1-7) enhances anti-aggregatory effects of the nitric oxide donor sodium nitroprusside

Journal of Cardiovascular Pharmacology

Volumn 46, Issue 4, 2005, Pages 459-463

  Rajendran, Sharmalar ^a   Chirkov, Yuliy Y ^a   Campbell, Duncan J ^b   Horowitz, John D ^a,c  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c QUEEN ELIZABETH HOSPITAL   (Australia)

Author keywords

Angiotensin II; Angiotensin (1 7); Nitric oxide; Platelet aggregation; U46619

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; ANGIOTENSIN[1-7]; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GUANYLATE CYCLASE; NITRIC OXIDE DONOR; NITROPRUSSIDE SODIUM; RADICAL; SUPEROXIDE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BLOOD VESSEL WALL; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HIGH RISK PATIENT; HUMAN; ISCHEMIC HEART DISEASE; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; ADULT; AGED; ANGIOTENSIN I; ANGIOTENSIN II; ANTIHYPERTENSIVE AGENTS; CORONARY DISEASE; DRUG SYNERGISM; FEMALE; HUMANS; MALE; MYOCARDIAL INFARCTION; NITRIC OXIDE DONORS; NITROPRUSSIDE; PEPTIDE FRAGMENTS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; VASOCONSTRICTOR AGENTS;

EID: 26044445236     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000176729.51819.a6     Document Type: Article

References (31)

1. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation. 2000;101:1899-1906.
2. Brunner H, Cockcroft JR, Deanfield J, et al. Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. J Hypertens. 2005;23:233-246.
3. Woods JD, Edwards JS, Ritter JM. Inhibition by nitroprusside of platelet calcium mobilization: evidence for reduced sensitivity to nitric oxide in essential hypertension. J Hypertens. 1993;11:1369-1373.
4. Anfossi G, Mularoni EM, Burzacca S, et al. Platelet resistance to nitrates in obesity and obese NIDDM, and normal platelet sensitivity to both insulin and nitrates in lean NIDDM. Diabetes Care. 1998;21:121-126.
5. Chirkov YY, Holmes AS, Chirkova LP, et al. Nitrate resistance in platelets from patients with stable angina pectoris. Circulation. 1999;100:129-134.
6. Chirkov YY, Holmes AS, Willoughby SR, et al. Stable angina and acute coronary syndromes are associated with nitric oxide resistance in platelets. J Am Coll Cardiol. 2001;37:1851-1857.
7. Chirkov YY, Holmes AS, Willoughby SR, et al. Association of aortic stenosis with platelet hyperaggregability and impaired responsiveness to nitric oxide. Am J Cardiol. 2002;90:551-554.
8. Chirkov YY, Holmes AS, Martelli JD, et al. Effect of perindopril on platelet nitric oxide resistance in patients with chronic heart failure secondary to ischemic left ventricular dysfunction. Am J Cardiol. 2004;93:1438-1440.
9. Griendling KK, Minieri CA, Ollerenshaw JD, et al. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res. 1994;74:1141-1148.
10. Rueckschloss U, Quinn MT, Holtz J, et al. Dose-dependent regulation of NAD(P)H oxidase expression by angiotensin II in human endothelial cells: protective effect of angiotensin II type 1 receptor blockade in patients with coronary artery disease. Arterioscler Thromb Vasc Biol. 2002;22:1845-1851.
11. Ding YA, MacIntyre DE, Kenyon CJ, et al. Angiotensin II effects on platelet function. J Hypertens. 1985;3(Suppl 3):S251-S253.
12. Touyz RM, Schiffrin EL. Effects of angiotensin II and endothelin-1 on platelet aggregation and cytosolic pH and free Ca2+ concentrations in essential hypertension. Hypertension. 1993;22:853-862.
13. Jagroop IA, Mikhailidis DP. Angiotensin II can induce and potentiate shape change in human platelets: effect of losartan. J Hum Hypertens. 2000;14:581-585.
14. Larsson PT, Schwieler JH, Wallen NH. Platelet activation during angiotensin II infusion in healthy volunteers. Blood Coagul Fibrinolysis. 2000;11:61-69.
15. Brosnihan KB, Li P, Ferrario CM. Angiotensin-(l-7) dilates canine coronary arteries through kinins and nitric oxide. Hypertension. 1996;27:523-528.
16. Roks AJ, van Geel PP, Pinto YM, et al. Angiotensin-(1-7) is a modulator of the human renin-angiotensin system. Hypertension. 1999;34:296-301.
17. Tallant EA, Diz DI, Ferrario CM. Antiproliferative actions of angiotensin-(1-7) in vascular smooth muscle. Hypertension. 1999;34:950-957.
18. Campbell DJ. Bioactive angiotensin peptides other than angiotensin II. In: Epstein M, Brunner HR, eds. Angiotensin II Receptor Antagonists. Philadelphia: Hanley and Belfus, Inc; 2001:9-27.
19. Guerra-Cuesta JI, Monton M, Rodriguez-Feo JA, et al. Effect of losartan on human platelet activation. J Hypertens. 1999;17:447-452.
20. Li P, Chappell MC, Ferrario CM, et al. Angiotensin-(1-7) augments bradykinin-induced vasodilation by competing with ACE and releasing nitric oxide. Hypertension. 1997;29:394-400.
21. Ren Y, Garvin JL, Carretero OA. Vasodilator action of angiotensin-(1-7) on isolated rabbit afferent arterioles. Hypertension. 2002;39:799-802.
22. Muthalif MM, Benter IF, Uddin MR, et al. Signal transduction mechanisms involved in angiotensin-(1-7)-stimulated arachidonic acid release and prostanoid synthesis in rabbit aortic smooth muscle cells. J Pharmacol Exp Ther. 1998;284:388-398.
23. Jaiswal N, Jaiswal RK, Tallant EA, et al. Alterations in prostaglandin production in spontaneously hypertensive rat smooth muscle cells. Hypertension. 1993;21:900-905.
24. Benter IF, Diz DI, Ferrario CM. Cardiovascular actions of angiotensin (1-7). Peptides. 1993;14:679-684.
25. Garcia NH, Garvin JL. Angiotensin 1-7 has a biphasic effect on fluid absorption in the proximal straight tubule. J Am Soc Nephrol. 1994;5:1133-1138.
26. Oliveira MA, Fortes ZB, Santos RA, et al. Synergistic effect of angiotensin-(1-7) on bradykinin arteriolar dilation in vivo. Peptides. 1999;20:1195-1201.
27. Haulica I, Bild W, Mihaila CN, et al. Biphasic effects of angiotensin (1-7) and its interactions with angiotensin II in rat aorta. J Renin Angiotensin Aldosterone Syst. 2003;4:124-128.
28. Kodama H, Fukuda K, Pan J, et al. Biphasic activation of the JAK/STAT pathway by angiotensin II in rat cardiomyocytes. Circ Res. 1998;82:244-250.
29. 3-cotransporter by angiotensin II type 1A receptor. Hypertension. 2002;40:707-712.
30. Santos RA, Simoes e Silva AC, Marie C, et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci USA. 2003;100:8258-8263.
31. Osei SY, Ahima RS, Minkes RK, et al. Differential responses to angiotensin-(1-7) in the feline mesenteric and hindquarters vascular beds. Eur J Pharmacol. 1993;234:35-42.